Phase
Startup
Uptake Bio
When cancer cells are subjected to oncological treatment for a longer period of time, they often develop a molecular shield that protects them from drugs and the immune system of the host. Consequently, the tumor starts growing again. In addition, a significant number of patients do not respond to the drugs at all due to this mechanism.
Based on recent and cutting-edge science at Lund University, Uptake Bio’s overarching aim is to develop a novel therapy that effectively destroys the shield and opens the tumor for the host’s potent attack. The tumor will be erased by the company’s proprietary antibody molecule. This is immune oncology in its essence.
The team behind Uptake Bio AB has a long and proven record of developing monoclonal antibodies for cancer therapy and cancer diagnostics, including the foundation of Alligator Bioscience AB, Immunovia AB, Cantagia AB and Diaprost AB.
Did you know?
Despite the revolution due to immunotherapy within cancer, there are still up to 60% non-responders in certain types of cancers.
Medicines for acute systemic inflammatory diseases
Cancer immunotherapies based in cell reprogramming
Cell factories for dairy processing
Automated microscopy image acquisition and analysis
Implants of magnesium alloys
Digital service for patients
Medical device that reduces pain during vein operation
Cloud-based solutions for genomics data
A reusable, user-friendly, and sustainable pregnancy test
Digital assistive device for post-surgical rehabilitation
Develops the first effective treatment for hypothyroidism
Builds gene therapy viral vectors
Early detection of pancreatic cancer
Bio-based vegan coating for fruits and vegetables
Equipment that improves the function of cultivated cells
Medtech solution for preventing pressure ulcers
Effective treatments for brain tumors
A new suturing choice for abdominal wall closure
Converting waste flows into valuable raw materials
Innovative systemic anti-inflammatory treatments
Safer medical needles for prostate biopsy